Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo.
AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
The Asthma and Allergy Foundation of America (AAFA) led a research study called Atopic Dermatitis in America . The purpose of this study is to shed light on the number of adults who deal with this frustrating skin condition. This week, AAFA has released early findings from the report. One surprising find from the study was the number of adults with AD who say it is moderate to severe. As many as 40% of the people surveyed said they had moderate-to-severe AD. Through this study, we hope to...
When Diana Hanley’s daughter Jamie was a baby, she wheezed every time she got sick. She had her first allergic reaction to eggs at 11 months. Around age 2, she was diagnosed with a peanut allergy. And because of constant hives, many foods were removed from her diet. Her family is now part of research to help families managing asthma and allergies. Read Jamie's story.
AAFA has joined with four other nonprofit organizations that serve people with eczema to launch “More Than Skin Deep.” This project will inform and shape the development of treatments for eczema. A main part the project is a patient-focused drug development (PFDD) meeting on Sept. 23, 2019, in Washington, D.C.
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .